Results 141 to 150 of about 50,069 (258)

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

The Colombian Medical Cannabis Paradox: A Scoping Review of Structural Barriers and Health Inequity. [PDF]

Int J Environ Res Public Health
Marín Arroyave OP, León Cruz P.
europepmc   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source

Concerns, Beliefs and Attitudes of Pharmacists About Medical Cannabis Use in Poland. [PDF]

Healthcare (Basel)
Merks P, Cameron J, Kazmierczak J, Białkowski A, Świetlik D, Borowska M, Wierzba W, Bołkun-Skórnicka U, Śliż D, Blicharska E, Fedorowski J, Vaillancourt R, Religioni U.   +12 more
europepmc   +1 more source

Maternal anorexia nervosa and risk of mental and neurodevelopmental morbidity in offspring

Child and Adolescent Mental Health, EarlyView.
Background Anorexia nervosa has the potential to affect fetal neurodevelopment. We examined the association between maternal anorexia nervosa and mental, substance‐related, and neurodevelopmental morbidity in offspring. Methods We conducted a retrospective cohort study of 1,269,370 children in Quebec, Canada, between 2006 and 2022.
Sam Amar, Gabriel Côté‐Corriveau, Mimi Israël, Howard Steiger, Nancy Low, Nicholas Chadi, Émilie Brousseau, Nahantara Lafleur, Nathalie Auger   +8 more
wiley   +1 more source

Medical Cannabis for Best Supportive Care of Patients Affected by Cancers of the Head and Neck: A Narrative Review. [PDF]

In Vivo
Perri F, Marciano ML, Zotta A, Pontone M, Piccirillo A, Casale M, DI Filippo P, Sarno MR, D' Aniello R, Cascella M, Maiolino P.   +10 more
europepmc   +1 more source

Cumulative effect of multiple health and social factors on adolescent mental well‐being: a cross‐sectional study in Catalonia

Child and Adolescent Mental Health, EarlyView.
Background While numerous studies have explored factors contributing to poor mental health, few have examined the combined influence of multiple health and social factors and their cumulative effect. This study specifically aimed to analyze the cumulative effect of multiple health and social factors associated with poor mental well‐being in school‐aged
Marina Robles‐Muñoz, Marina Bosque‐Prous, Cinta Folch, Helena González‐Casals, Gemma Drou‐Roget, Cristina Torrado‐Cortés, Carles Muntaner, Albert Espelt   +7 more
wiley   +1 more source

Medical Cannabis Formulations, Administration Routes, and Dosing: Perspectives of Patients With Cancer Who Consume. [PDF]

Clin Ther
Nayak MM, Chai PR, Tung S, Revette A, Braun IM.   +4 more
europepmc   +1 more source

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)

Epilepsia, EarlyView.
Abstract Objective This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).
Dennis J. Dlugos, Ingrid E. Scheffer, Jacqueline A. French, David G. Vossler, Chad Orevillo, Shikha Polega, Randall Kaye, and the LP352‐201 Study Investigators, Kore Liow, Ena Zhu, Jennifer Waldron, Hayley Groubert, Alexis Anderson, Pavel Klein, Salman Hashmi, Shicong Ye, Anita Farhi, David Vossler, Dione M. Froman, Shannon L. Hoffman‐Huffaker, Ki Hyeong Lee, AnnaLyn Dallas, Amir Arain, Laura Beeler, Michael Macken, Irena Bellinski, Elizabeth Cunningham, James Renfroe, Shezsay Colbert, Robert Hogan, Patty Schaefer, Susan Shaw, Sheetal Desai, Ahmed Sadek, Haile Robertson, Kamil Detyniecki, Anabela Cieslicki, Ruben Kuzniecky, Sarah Goodman, Selim Benbadis, Marina Azevedo, Sami Aboumatar, Julie Biel, Nilika Singhal, Emerald Wan, Evan Fertig, Hannah Hart, Debopam Samanta, Sarah Hankins, Steven Wolf, Patricia Pena, Robert Nahouraii, M. J. Mari, David Burdette, Stephanie Mueller, Karen Keough, Victoria Henderson, Talitha Durgin, Terence O’Brien, Rafael Smith, Jack Germaine, Kate Riney, Lori Anthony, David Reutens, Kimberley Irwin, Michael Fahey, Melissa Batt, Stephanie Kaladis, Kasthoori Jeyachanthiran, Ingrid Scheffer, Rebecca Wharrie, Greesha Zacharia, Brittany Walsh, Heather Robinson, Sharon Ganter   +74 more
wiley   +1 more source

Medical cannabis legalization and the use of illicit drugs, alcohol, and tobacco. [PDF]

J Cannabis Res
Al Hallaj H, Barakat Z.
europepmc   +1 more source